Newcastle University
Toggle Main Menu
Toggle Search
Home
Browse
Latest
Policies
About
Home
Browse
Latest
Policies
About
ePrints
Browse by author
Browsing publications by
Dr Stuart McCracken.
Newcastle Authors
Title
Year
Full text
Dr Stuart McCracken
Jonathan Aning
Vincent Gnanapragasam
MRI-based nomogram for the prediction of prostate cancer diagnosis: A multi-centre validated patient–physician decision tool
2023
Dr Stuart McCracken
Dr Tobias Page
Re-evaluating the diagnostic efficacy of PSA as a referral test to detect clinically significant prostate cancer in contemporary MRI-based image-guided biopsy pathways
2023
Dr Beth Adamson
Nicholas Brittain
Dr Laura Walker
Ruaridh Duncan
Dr Sara Luzzi
et al.
The catalytic subunit of DNA-PK regulates transcription and splicing of AR in advanced prostate cancer
2023
Dr Stuart McCracken
Assessment of Return to Baseline Urinary and Sexual Function Following Primary Focal Cryotherapy for Nonmetastatic Prostate Cancer
2021
Dr Stuart McCracken
Feasibility of Comparative Health Research Outcome of Novel Surgery in prostate cancer (IP4-CHRONOS): statistical analysis plan for the randomised feasibility phase of the CHRONOS study
2021
Dr Stuart McCracken
Professor Damian Greene
Focal therapy compared to radical prostatectomy for non-metastatic prostate cancer: a propensity score-matched study
2021
Dr Stuart McCracken
Comparative Healthcare Research Outcomes of Novel Surgery in prostate cancer (IP4-CHRONOS): A prospective, multi-centre therapeutic phase II parallel Randomised Control Trial
2020
Alex Bainbridge
Dr Scott Walker
Joseph Smith
Yi Min Ng Ng
Huw Thomas
et al.
IKBKE activity enhances AR levels in advanced prostate cancer via modulation of the Hippo pathway
2020
Evangelia Kounatidou
Dr Sirintra Nakjang
Dr Stuart McCracken
Professor Craig Robson
Dr Dominic Jones
et al.
A novel CRISPR-engineered prostate cancer cell line defines the AR-V transcriptome and identifies PARP inhibitor sensitivities
2019
Dr Stuart McCracken
Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry
2019
Dr Urszula McClurg
Svitlana Korolchuk
Dr Stuart McCracken
Professor Rakesh Heer
Laura Wilson
et al.
Human
ex vivo
prostate tissue model system identifies ING3 as an oncoprotein
2018
Dr Urszula McClurg
Dr Mahsa Azizyan
Dr Sirintra Nakjang
Dr Stuart McCracken
Professor Craig Robson
et al.
Molecular mechanism of the TP53-MDM2-AR-AKT signalling network regulation by USP12
2018
Dr Urszula McClurg
Dr Sirintra Nakjang
Dr Stuart McCracken
Professor Craig Robson
A novel anti-androgen candidate galeterone acts by targeting USP12, a deubiquitinating enzyme that controls prostate cancer growth and survival
2016
Dr Urszula McClurg
Victoria Harle
Dr Scott Walker
Dr Kelly Coffey
Dr Luke Gaughan
et al.
Ubiquitin-specific protease 12 interacting partners Uaf-1 and WDR20 are potential therapeutic targets in prostate cancer
2015
Dr Stuart McCracken
Professor Rakesh Heer
Penile strangulation by a substantial metal napkin ring: successful removal with medtronic midas rex® legend® stylus® drill system
2013
Dr Stuart McCracken
Dr Kanagasabai Sahadevan
Professor Hing Leung
SPRY2 loss enhances ErbB trafficking and PI3K/AKT signalling to drive human and mouse prostate carcinogenesis
2012
Dr Stuart McCracken
ERK5 signalling in prostate cancer promotes an invasive phenotype
2011
Dr Luke Gaughan
Dr Stuart McCracken
Professor Craig Robson
Dr Steven Powell
FUS/TLS Is a Novel Mediator of Androgen-Dependent Cell-Cycle Progression and Prostate Cancer Growth
2011
Dr Luke Gaughan
Dr Jacqueline Stockley
Nan Wang
Dr Stuart McCracken
Dr Kelly Coffey
et al.
Regulation of the androgen receptor by SET9-mediated methylation
2011
Dr Stuart McCracken
Garrett Durkan
Rob Pickard
Professor Craig Robson
Diagnosis and management of prostate cancer in the older man
2010
Professor Hing Leung
Dr Arthur Mckie
Dr Stuart McCracken
Dr Helen Maitland
Dr Sharon Olijslagers
et al.
Loss of Sprouty2 Drives an Invasive Phenotype in Prostate Cancer and May Co-operate with HER2/3 in a Subgroup with Aggressive Disease
2009
Dr Stuart McCracken
Professor Rakesh Heer
Dr Marie Mathers
Benjamin Jenkins
Professor Craig Robson
et al.
Aberrant expression of extracellular signal-regulated kinase 5 in human prostate cancer
2008
Dr Stuart McCracken
Professor David Neal
Professor Hing Leung
Mitogenic growth signalling, DNA replication licensing, and survival are linked in prostate cancer
2007
Dr Ian Logan
Dr Luke Gaughan
Dr Stuart McCracken
Dr Vasileia Sapountzi
Professor Hing Leung
et al.
Human PIRH2 enhances androgen receptor signaling through inhibition of histone deacetylase 1 and is overexpressed in prostate cancer
2006
Bharat Gowardhan
David Douglas
Dr Marie Mathers
Dr Arthur Mckie
Dr Stuart McCracken
et al.
Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer
2005
Dr Stuart McCracken
Benjamin Jenkins
Professor Rakesh Heer
Dr Marie Mathers
Professor Craig Robson
et al.
Expression analysis of the MEK5/ERK5 signalling pathway in human prostate cancer
2005
Dr Luke Gaughan
Professor Craig Robson
Dr Stuart McCracken
Professor David Neal
Huntingtin interacting protein 1 modulates the transcriptional activity of nuclear hormone receptors
2005